ADAnastasya S. Doronkina

Anastasya S. Doronkina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anastasya S. Doronkina has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Antinociceptive effects of palmitoylethanolamide and stearoylethanolamide upon PPARγ receptor blockade in rats with peripheral neuropathy

    by Anastasya S. Doronkina, А. R. Gavrilchik, A. A. Rudak

    Objectives. To investigate the role of PPARγ receptors in realization of the antinociceptive effects of PEA and SEA in rats with peripheral neuropathy. Material and methods. Interaction of palmitoylethanolamide and stearoylethanolamide with the PPARγ receptor was studied using the molecular computer modeling to evaluate the binding affinity and stability of these complexes. The antinociceptive effects of acylethanolamides on PPARγ receptor blockade in rats with peripheral mononeuropathy were studied. Results. Computer molecular modeling between acylethanolamides and the PPARγ receptor has shown the formation of stable complexes characterized by the formation of intermolecular hydrogen bonds and a network of hydrophobic interactions. The obtained results substantiate the feasibility of an experimental assessment of the involvement of PPARγ receptors in the antinociceptive effects of acylethanolamides. Administration of palmitoylethanolamide and stearoylethanolamide to rats with peripheral mononeuropathy with PPARγ receptor blockade reduced the threshold of nociceptive reactions and the latent period of nociceptive reactions compared with the values of the group administered with acylethanolamides without blockade. Single administration of palmitoylethanolamide with PPARγ receptor blockade reduced the area and intensity of the ipsilateral limb imprint in animals with neuropathy compared with administration of the test substance without PPARγ receptor blockade. Conclusions. The realization of the antinociceptive effects of palmitoylethanolamide and stearoylethanamide in response to thermal and mechanical stimuli is mediated by PPARγ receptors.

  • Open Access

    Gene Therapy Using a VEGF165/Ang-1 Plasmid Construct: Evaluation of Vascular Density in Chronic Hindlimb Ischemia in Rats

    by V. G. Bogdan, T. A. Filipovich, E. V. Fiodorova, I. P. Zhavoronok, A. S. Doronkina, А. V. Yantsevich, S. V. Mankovskaya, В. Г. Богдан, Т. А. Филипович, Е. В. Федорова, et al.

    Introduction . The prevalence of chronic lower limb ischemia among individuals over 50 years of age does not exceed 8 % . However, in the presence of risk factors such as smoking, diabetes mellitus, or hypertension, the risk of its development increases to 30 % . This study evaluates the efficacy of therapeutic angiogenesis using a combined circular DNA-based construct. Objective . To determine, in an in vivo experiment, the features of the dynamics of blood vessel density changes in the ischemic muscles of the rat hind limb after local application of a plasmid construct containing gene segments encoding vascular endothelial growth factor 165 and angiopoietin-1 (pcDNA_VEGF165/Ang-1). Materials and Methods . Three observation groups were formed: «CHI» (chronic hindlimb ischemia without treatment; n=12), «CHI + PSS» (administration of pyrogen-free physiological saline, 200 μL; n=12), and the experimental «CHI + VEGF165/Ang-1» group (administration of pcDNA_VEGF165/Ang-1 at a dose of 100 μg/animal; n=24). The solutions were administered once intramuscularly into the animal’s right hindlimb. An immunohistochemical examination of the skeletal muscle tissue of the thigh and lower leg was performed using monoclonal antibodies against blood vessel endothelial cells (CD31) and against smooth muscle α-actin (α-SMA). Results . The use of the combined VEGF165/Ang-1 plasmid led to a statistically significant stimulation of angiogenesis and arteriogenesis, which made it possible to completely restore vascular density in the ischemic limb to the level of a healthy limb. In contrast to the persistent ischemic decrease in the number of microvessels in the control groups («CHI» and «CHI + PSS»), gene therapy ensured a steady increase in the vascular network. By day 28, the density of CD31-positive capillaries in the thigh and lower leg increased by 55.3 % and 33.3 %, respectively, and the density of α-SMA-positive arterioles increased by 42.2 % and 44.5 %, respectively, reaching normal values. Conclusion . The use of a domestic plasmid construct containing the genes of the angiogenesis-activating proteins VEGF165 and Ang-1 (pcDNA_VEGF165/Ang-1) in chronic hindlimb ischemia in rats accelerates capillarogenesis and arteriogenesis in ischemic lower leg muscles starting from day 14, and in the thigh muscles from day 28 after administration, as evidenced by a significant increase in the density values of CD31-positive capillaries and α-SMA-positive arterioles.

  • Open Access

    Angiogenic effects of combined gene therapeutic construction pcDNA_VEGF165/Ang-1 in conditions of modeling chronic limb ischemia in vivo

    by V. G. Bogdan, T. A. Filipovich, E. V. Fiodorova, I. P. Zhavoronok, A. S. Doron’kIna, S. G. Lepeshko, S. V. Man’kOvskaya

    The combined plasmid construct pcDNA_VEGF165/Ang-1 has a pronounced angiogenic effect under the conditions of the modeled experimental chronic insufficiency of arterial blood supply to the limb. A single local administration of pcDNA_VEGF165/Ang-1 at a dose of 100 μg into the ischemic skeletal muscle of laboratory animals starting from the 14th day after therapy stimulates the formation of microcirculatory bed vessels with a statistically significant increase in the number of capillaries. The use of the gene therapeutic substance pcDNA_VEGF165/Ang-1 allows for complete restoration of impaired blood supply in the muscles of the thigh and lower leg of the rats by the 28th day of observation, creates conditions for maintaining a long-term positive effect until the end of the experiment (42nd day) while maintaining the number of blood vessels in one muscle fiber not lower than the healthy tissue indicator.


  • Open Access

    Angiogenic and antinociceptive effects of the genotherapy construction pcDNA_VEGF165 in the conditions of chronic limb ischemia in an in vivo experiment

    by V. G. Bogdan, А. С. Доронькина, I. P. Zhavoronok, E. V. Fedorova, T. A. Filippovich, S. G. Lepeshko, S. V. Mankovskaya

    For the first time, an in vivo experiment has established a positive combined (angiogenic and antinociceptive) effect of using the domestic genetically engineered construction pcDNA_VEGF165 under conditions of simulated limb muscle ischemia. A plasmid with a gene encoding the protein VEGF165 (pcDNA_VEGF165) may be the basis for creating the first gene therapy drugs in the Republic of Belarus.


  • Open Access

    Virtual screening of the biological activity of fatty acid amides

    by А. С. Доронькина, A. A. Rudak, I. P. Zhavoronok, V. G. Bogdan

    Виртуальный скрининг биологической активности амидов жирных кислот


  • Open Access

    Biological effects of butanoyl ethanolamide and capryloyl ethanolamide in rats: antinociceptive and side effects

    by Надежда Ивановна Счастная, Ирина Петровна Жаворонок, Анастасия Сергеевна Доронькина, Марина Сергеевна Кукса, В. Филатова Д, Екатерина Николаевна Чудиловская, Марина Владимировна Лисовская, Александр Леонидович Михальчук, Алла Юрьевна Молчанова

    Введение. Одним из перспективных направлений разработки новых фармакологических препаратов для купирования боли и воспаления является изучение биологического действия липидных молекул, в том числе и этаноламидов жирных кислот. Цель исследования – изучение влияния бутаноилэтаноламида (butanoylethanolamide, ВЕА) и каприлоилэтаноламида (caprinoylethanolamide, СЕА) на ноцицептивные реакции, биохимические и гистологические изменения у здоровых животных и на уровень болевой чувствительности при моделировании нейропатии и артрита. Методика. Исследование выполнено на крысах-самцах Wistar (n=71). Ноцицептивную чувствительность оценивали по изменению показателей порога ноцицептивной реакции (ПНР) и по динамике латентного периода ноцицептивной реакции (ЛПНР). Общий анализ крови выполняли с использованием гематологического ветеринарного анализатора Nihon MEK 6450К (Япония). Биохимические исследования проводили с помощью биохимического анализатора BS-200 (MINDRAY, Китай) c применением коммерческих наборов фирмы Диасенс (Беларусь). Результаты. Внутрижелудочное введение ВЕА здоровым животным во всех исследуемых дозах не приводило к статистически значимым изменениям ПНР и ЛПНР по сравнению с их начальными значениями (p>0,05). СЕА в дозе 100 мг/кг вызывал снижение ноцицептивной чувствительности на механическое воздействие (pЗаключение. Однократное внутрижелудочное введение ВЕА во всех тестируемых дозах не влияет на чувствительность к ноцицептивным стимулам. CЕА в дозе 100 мг/кг вызывает слабый антиноцицептивный эффект в ответ на механическое воздействие. Выраженность изменений функциональной активности печени и почек у экспериментальных животных зависит от дозы исследуемых субстанций. При моделирования нейропатии и артрита отмечен анальгетический эффект ВЕА и СЕА в дозе 100 мг/кг.


  • Open Access

    Physiological effects of fatty acid amides in experimental peripheral neuropathy with pharmacological blockade of GPR55 receptors

    by А. С. Доронькина, I. P. Zhavaranak, V. G. Bogdan

    Objective. To study the effect of fatty acid amides during pharmacologic blockade of GPR55 receptors on nociceptive sensitivity and gait patterns in rats in normal and experimental peripheral neuropathy.Materials and methods. The study was carried out on male Wister rats (n=125), divided into 18 groups. The role of fatty acid amides in blockade of GPR55 receptors by administration of the antagonist O-1918 on nociceptive responses and gait parameters in healthy rats and in animals after the formation of neuropathy (NP) was studied.Results. It was found that administration of O-1918 to healthy rats and rats with neuropathy at a dose of 1 mg/kg resulted in a statistically significant decrease in the values of nociceptive reactions and gait parameters. In healthy rats and animals after ligation of the sciatic nerve against the background of blockade of GPR55 receptors PGlyA had a pronounced antinociceptive effect, which was confirmed by a significant increase in the values of nociceptive sensitivity, as well as normalization of gait.Conclusion. The analgesic effect after administration of PEA and SEA is probably the result of the interaction of the above FAAs with membrane orphan receptors. At the same time, the antinociceptive effect of PGlyA probably results from the activation of receptors belonging to another class, presumably vanilloid receptors of the first type.


  • Open Access

    Profile of pro- and anti-inflammatory cytokines during injection of fatty acid amides with ethanolamine and glycine in modeling peripheral neuropathy

    by А. С. Доронькина, I. P. Zhavoronok, V. G. Bogdan

    The effect of fatty acid amides during the blockade of membrane orphan GPR18, GPR55 and nuclear PPARα receptors on the level of pro- and anti-inflammatory cytokines in rats with experimental peripheral neuropathy was studied. It has been proven that the anti-inflammatory action of PEA and SEA in experimental animals with neuropathy is carried out through nuclear PPARα receptors. However, PGlyA has no anti-inflamatory effects in a rat model of peripheral neuropathy.


  • Open Access

    Effects of fatty acid amides with ethanolamine and glycine on nociceptive reactions and gait parameters in rats in normal and experimental peripheral mononeuropathy

    by А. С. Доронькина, A. L. Mikhalchuk, S. V. Goubkin, A. Yu. Molchanova, V. G. Bogdan

    Изучено влияние амидов жирных кислот с этаноламином и глицином на паттерны походки и ноцицептивные реакции у здоровых крыс и крыс с экспериментальной периферической нейропатией. Показано, что при купировании нейропатической боли и восстановлении параметров походки пальмитоилэтаноламид и стеароилэтаноламид более эффективны, чем пальмитамид глицина.